February 29, 2012 - Shire plc , the global specialty biopharmaceutical company, announces that on February 28, 2012 the following Persons Discharging Managerial Responsibility ("PDMRs") were granted awards under the Shire Portfolio Share Plan (PSP).
Stock Appreciation Right Awards ("SAR Awards") under Part A of the PSP
SAR Awards will normally vest after three years, subject to any performance targets having been satisfied. No consideration is payable for these awards.
Type of Security1 No of Ordinary Exercise price Shares/ADSs
Angus Russell 2 ADSs 47,861 $105.50
Graham Hetherington 2 Ordinary Shares 55,554 £22.22
Michael Cola ADSs 9,683 $105.50
Barbara Deptula ADSs 5,645 $105.50
Sylvie Gregoire ADSs 10,409 $105.50
Tatjana May Ordinary Shares 20,180 £22.22
Kevin Rakin ADSs 6,778 $105.50
Performance Share Awards ("PSA Awards") under Part B of the PSP
PSA Awards will normally vest after three years, subject to any performance targets having been satisfied. No consideration is payable for these awards.
Type of Security No of Ordinary 1 Shares/ADSs
Angus Russell 2 ADSs 35,896
Graham Hetherington 2 Ordinary Shares 40,740
Michael Cola ADSs 7,101
Barbara Deptula ADSs 4,064
Sylvie Gregoire ADSs 7,633
Tatjana May Ordinary Shares 14,530
Kevin Rakin ADSs 4,971
1. One ADS is equal to three Shire ordinary shares.
2. Vesting of awards granted to Executive Directors is subject to performance targets.
This notification is made to satisfy the Company's obligations under 3.1.4(R) (1)(a) of the Disclosure and Transparency Rules.
Deputy Company Secretary
For further information please contact:
Investor Eric Rojas email@example.com +1 781 482 0999 Relations
Sarah Elton-Farr firstname.lastname@example.org +44 1256 894157
Notes to editors
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.